Journal
Blood Advances
Publication Date
10-10-2023
Volume
7
Issue
19
First Page
5835
Last Page
5842
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2023010151
Rights and Permissions
Oh ST, Mesa RA, Harrison CN, Bose P, Gerds AT, Gupta V, Scott BL, Kiladjian JJ, Lucchesi A, Kong T, Buckley SA, Tyavanagimatt S, Harder BG, Roman-Torres K, Smith J, Craig AR, Mascarenhas J, Verstovsek S. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv. 2023 Oct 10;7(19):5835-5842. doi: 10.1182/bloodadvances.2023010151. © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Recommended Citation
Oh, Stephen T; Kong, Tim; and et al., "Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis." Blood Advances. 7, 19. 5835 - 5842. (2023).
https://digitalcommons.wustl.edu/oa_4/3000
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
